Skip to main content
Equibles
PBYI logo

PBYI

Puma Biotechnology, Inc.
$8.53 +0.13 (+1.55%) At close · Jul 17
Market Cap
$434.17M
Shares
50,899,456

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.53 Open$8.28 Day$8.25–8.64 52W$3.03–8.66 Avg vol 30d318K Short int3.6M · 7.1% float · 8.5d Short vol58% Last earningsMay 7, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 7
Up next
Next earnings call
Aug 6, 2026 Est · unconfirmed · in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 7, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 18.8 · elevated Equity put/call 0.73
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +32%
      above
      Price vs 50-day avg +14%
      above
      RSI (14) 66
      neutral
      MACD trend Positive
      52-week position 98%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +18%
      trailing
      6-month return +33%
      trailing
      YTD return +43%
      this year
      Relative strength +25%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $7 › 200d $6 — 50d above 200d
      Institutional flow Accumulating
      10 of 157 funds reported for Jun 30 · net +12.1K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      7.13% of float · ▼ -1.9% MoM · 8.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      157 holders — near 3-yr high, broad support
      Squeeze score 72
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +356%
      Y/Y
      EPS growth −2%
      Y/Y
      Free cash flow $41.7M
      Valuation P/E 17.8
      in line
      Balance sheet $7.1M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 70%
      annualized · 1-yr
      Max drawdown −26%
      past year
      ATR 4.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record
      Latest guidance · from the 8-K filed May 7, 2026
      Second Quarter 2026
      Net Product Revenue Initiated $50M – $52M
      prior qtr $44.81M midpoint +13.8% QoQ
      Royalty Revenue Initiated $2M – $3M
      prior qtr $44.81M midpoint −94.4% QoQ
      License Revenue Initiated $0
      prior qtr $44.81M midpoint −100.0% QoQ
      Total Revenue Initiated $52M – $55M
      prior qtr $44.81M midpoint +19.4% QoQ
      Gross to Net Adjustment Maintained 27% – 28%
      New Full Year 2026
      Net Product Revenue Initiated $202M – $206M
      prior FY $228.37M midpoint −10.7% Y/Y
      Royalty Revenue Initiated $20M – $23M
      prior FY $228.37M midpoint −90.6% Y/Y
      License Revenue Initiated $0
      prior FY $228.37M midpoint −100.0% Y/Y
      Total Revenue Initiated $222M – $229M
      prior FY $228.37M midpoint −1.3% Y/Y
      Gross to Net Adjustment Initiated 26.5% – 27.5%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +32% Bullish
      Price vs 50-day avg
      +14% Bullish
      RSI (14)
      66 Neutral
      MACD trend
      Positive Bullish
      52-week position
      98% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $7 › 200d $6 — 50d above 200d
      Institutional flow Accumulating
      10 of 157 funds reported for Jun 30 · net +12.1K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      7.13% of float · ▼ -1.9% MoM · 8.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      157 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $3 Now $9 · 98% 52-wk high $9
      vs 200-day avg +32% vs 50-day avg +14%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Non-GAAP adjusted net loss non-GAAP -$1.9M Q1 2026 —
      bottles of NERLYNX sold 2,328 Q1 2026 call —
      inventory decrease 439 Q1 2026 call —
      new prescriptions change 25% Q1 2026 vs Q4 2025 call —
      total prescriptions change -4% Q1 2026 vs Q4 2025 call —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PBYI
      Puma Biotechnology, Inc.
      this stock
      		$434.17M +43.4% +3.3% 17.8 7.1%
      ONC
      BeOne Medicines Ltd.
      		 $450.95B +2.7% +22179.2% 917.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $123.26B +7.1% +46.2% 28.8 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $70.94B -12.2% +20.8% 16.5 3.3%
      ARGX
      Argenx SE
      		 $53.84B +2.3% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      158
      % held
      71.2%
      Reported
      10 of 157
      Top holder
      ACORN CAPITAL ADVISORS, L…
      Held Float
      View
      Held by Funds
      Fund positions
      179
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      3.6M
      Days to cover
      8.5d
      Change
      -70.3K sh
      View
      Short Volume
      Short vol %
      58%
      As of
      Jul 17, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      5.3K
      Value
      $43.3K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      36.5%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Donna Shalala
      Amount
      $1.0K–$15.0K
      Traded
      May 15, 2019
      View
      Financials
      Financials
      Revenue (FY)
      $228.4M
      Net income (FY)
      $31.1M
      EPS diluted
      $0.61
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      7
      View
      Proposed Sales
      Value
      $364.0K
      Shares
      44.1K
      Filed
      Jul 6, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 7, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PBYI +6.6% +18.0% +32.9% +5.2% +43.4%
      SPY -1.5% +0.3% +7.8% -0.5% +9.0%
      vs SPY +8.2% +17.7% +25.0% +5.7% +34.4%
      Key facts CIK 1401667 CUSIP 74587V107 13F (30d) 17 filings 12 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)